Posted on Jan. 12, 2022, 9:22 p.m.
One month after its authorization in the United States, the treatment of Astrazeneca will increase the American arsenal of prevention against Covid. Washington is in talks with the lab to order 500,000 doses of its antibody-based drug against the coronavirus.
The American administration is “in the process of ordering” these doses, intended for immunocompromised people, who respond poorly, or not, to vaccines, and effective against the Omicron variant, said a representative of the government of Joe Biden on Wednesday. The new order will bring total US purchases to 1.2 million doses, all expected by the end of March, AstraZeneca said in a statement.
Administered as two injections
The results of AstraZeneca’s first study on its product, in June 2021, were inconclusive: they revealed that the combination of antibodies was only 33% effective in preventing symptoms of Covid-19 in people. exposed to the virus. But since then, two studies have shown the cocktail to be very effective in preventing symptoms in those at risk who are infected, halving their risk of developing serious illness or dying.
This medication, administered as two injections (and not as an infusion like the others, which makes it easier to use), can therefore be used in addition to vaccines, or to protect immunocompromised people, who have no could not receive a dose of vaccine. The main groups of eligible patients are those with cancer or those with weakened immune systems.